CL2012003209A1 - Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico. - Google Patents

Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.

Info

Publication number
CL2012003209A1
CL2012003209A1 CL2012003209A CL2012003209A CL2012003209A1 CL 2012003209 A1 CL2012003209 A1 CL 2012003209A1 CL 2012003209 A CL2012003209 A CL 2012003209A CL 2012003209 A CL2012003209 A CL 2012003209A CL 2012003209 A1 CL2012003209 A1 CL 2012003209A1
Authority
CL
Chile
Prior art keywords
pentoxifylline
nanoparticles
plga
lactic
poly
Prior art date
Application number
CL2012003209A
Other languages
English (en)
Inventor
Duran Paula Soledad Ibarra
Ortiz Cristian Andres Vilos
Cumplido Luis Velasquez
Serrano Teresa Pelissier
Fuenzalida Claudio Aurelio Laurido
Kunstamnn Alejandro Hernandez
Cordova Luis Ernesto Constandil
Original Assignee
Univ Santiago Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Santiago Chile filed Critical Univ Santiago Chile
Priority to CL2012003209A priority Critical patent/CL2012003209A1/es
Publication of CL2012003209A1 publication Critical patent/CL2012003209A1/es
Priority to MX2015006187A priority patent/MX2015006187A/es
Priority to PCT/CL2013/000084 priority patent/WO2014075203A1/es
Priority to BR112015011294A priority patent/BR112015011294A8/pt
Priority to US14/443,260 priority patent/US20150283095A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método de síntesis de nanopartículas de ácido poli (láctico-glicólico) (PLGA) con pentoxifilina; composición farmacéutica que comprende nanopartículas de PLGA con pentoxifilina encapsulada; y uso de nanopartículas de PLGA cargadas con pentoxifilina en el tratamiento del alivio y prevención del dolor crónico.
CL2012003209A 2012-11-16 2012-11-16 Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico. CL2012003209A1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CL2012003209A CL2012003209A1 (es) 2012-11-16 2012-11-16 Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
MX2015006187A MX2015006187A (es) 2012-11-16 2013-11-15 Nanoparticulas con polimero biodegradable y biocompatible acido poli(lactico-glicolico)(plga) cargadas con el farmaco de uso humano pentoxifilina.
PCT/CL2013/000084 WO2014075203A1 (es) 2012-11-16 2013-11-15 Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina
BR112015011294A BR112015011294A8 (pt) 2012-11-16 2013-11-15 nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas
US14/443,260 US20150283095A1 (en) 2012-11-16 2013-11-15 Nanoparticles with biodegradable and biocompatible polymer plga, loaded with the drug for human use pentoxifylline

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2012003209A CL2012003209A1 (es) 2012-11-16 2012-11-16 Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.

Publications (1)

Publication Number Publication Date
CL2012003209A1 true CL2012003209A1 (es) 2013-04-19

Family

ID=50730445

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003209A CL2012003209A1 (es) 2012-11-16 2012-11-16 Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.

Country Status (5)

Country Link
US (1) US20150283095A1 (es)
BR (1) BR112015011294A8 (es)
CL (1) CL2012003209A1 (es)
MX (1) MX2015006187A (es)
WO (1) WO2014075203A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
US20240398852A1 (en) * 2021-09-29 2024-12-05 Oncour Pharma, Inc. Negatively charged particles for the treatment of inflammation-related burn injuries
CN114870023A (zh) * 2022-05-12 2022-08-09 成都市第三人民医院 一种缓释的视神经保护药物纳米合成材料及其制备方法和应用
CN116585488B (zh) * 2023-05-08 2024-02-23 广东省第二人民医院（广东省卫生应急医院） 一种罗哌卡因纳米载药材料及其制备方法
CN116869968B (zh) * 2023-09-07 2023-11-24 四川大学 一种靶向大脑和脑胶质瘤的纳米粒及其合成方法、应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
WO2008105773A2 (en) * 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
KR100853309B1 (ko) * 2006-11-01 2008-08-20 나재운 시프로플록사신이 담지된 폴리락타이드글리콜라이드공중합체의 서방출 및 생분해성 나노입자 및 그 제조방법
US20120238590A1 (en) * 2010-09-13 2012-09-20 Tenera Therapeutics, LLC Delaware Compositions for treating cancer-related fatigue and methods of screening thereof
WO2013185032A1 (en) * 2012-06-07 2013-12-12 President And Fellows Of Harvard College Nanotherapeutics for drug targeting

Also Published As

Publication number Publication date
US20150283095A1 (en) 2015-10-08
WO2014075203A1 (es) 2014-05-22
BR112015011294A2 (pt) 2017-07-11
WO2014075203A8 (es) 2014-07-17
MX2015006187A (es) 2015-08-10
BR112015011294A8 (pt) 2019-10-22

Similar Documents

Publication Publication Date Title
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CR20150386A (es) Composiciones de nanoparticulas de albumina y paclitaxel
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
GB201411465D0 (en) Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
CL2014002726A1 (es) Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14).
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
PH12015500115A1 (en) Glucagon analogues
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX379456B (es) Inhibidores de fde9 con estructura básica de imidazotriazinona y estructura básica de imidazopirazinona en el tratamiento de enfermedades periféricas.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
SI3168214T1 (sl) Substituiran 2-tiokso-imidazolidin-4-on in njegovi spiro analogi, aktivne proti rakave sestavine, farmacevtski sestavki, medicinski pripravki, postopek za zdravljenje raka prostate
WO2014153385A3 (en) Methods of treating metabolic disorders
MX382476B (es) Dispersiones solidas de bendamustina e infusion continua.
CL2012003209A1 (es) Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині